Sponsor Overview
Explore verified public information about Novo Nordisk's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Novo Nordisk may upon request make a medicine available which has not been authorised for the condition on a named patient basis, when this is expected to help the patient with a life-threatening, long-lasting or seriously disabling illness that cannot be treated satisfactorily with authorised medicines, or a patient who has a disease for which no medicine has yet been authorised.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Congenital Haemophilia
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Primary Hyperoxaluria Type 1 (PH1)
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.